PatientsVille.com Logo


470 Medical Research Studies

Up-to-date List of 470 Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest 470 Medical Research Studies

Rank Status Study
1 Recruiting Efficacy Study Comparing 2% Chlorhexidine in 70% Isopropyl Alcohol Versus 2% Aqueous Chlorhexidine
Condition: Anti-infecting Agents, Local
Interventions: Drug: 2% aqueous chlorhexidine;   Drug: 2% Chlorhexidine 70% isopropyl alcohol
Outcome Measures: Bacterial colony count as assessed by pre- and post cleansing skin swab culture.;   Immediate or late Skin reactions.
2 Unknown  Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children
Conditions: Tuberculosis;   HIV
Interventions: Procedure: Interferon-Gamma Release Assay;   Drug: RT-23
Outcome Measure:
3 Recruiting A Double-blind Evaluation of Adverse Effects of Bath With Wipes Impregnated With 2% Chlorhexidine Versus Placebo
Condition: Bed Bathing
Interventions: Procedure: Standardization phase;   Procedure: Control bath;   Procedure: Bath with chlorhexidine
Outcome Measures: Skin reaction to chlorhexidine;   Comparison of bacterial colony count of skin.
4 Recruiting ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
Condition: Skin Infections, Bacterial
Intervention: Drug: ALTARGO(retapamulin)
Outcome Measures: The number of adverse event after ALTARGO(retapamulin) treatment;   The number of unexpected adverse event after ALTARGO(retapamulin) treatment;   The number of serious adverse event after ALTARGO(retapamulin) treatment;   Effectiveness of ALTARGO(retapamulin) treatment
5 Recruiting A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention
Condition: Chronic and Acute Wounds, Diabetic Foot Ulcers and Venous Leg Ulcers Below the Knee
Interventions: Device: WoundWand™ Debridement Device;   Device: Standard of Care sharp debridement
Outcome Measures: bacterial diversity and number of bacteria;   Reduction in wound size;   Health economic data;   Wound closure
6 Recruiting Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Isoniazid (INH);   Drug: Placebo for isoniazid (INH)
Outcome Measures: Grade 3 or higher adverse events (AEs);   Fetal death;   Fetus small for gestational age;   Premature birth of infant (less than 37 weeks gestation);   Low birth weight of infant;   Congenital anomalies of infant;   Grade 3 or higher clinical or laboratory AEs for fetus/infant;   HIV infection of infant;   Maternal TB;   Infant TB;   Death of infant;   Death of mother;   Resistance to INH in isolates of Mycobacterium tuberculosis from mothers who develop culture-confirmed TB;   Resistance to INH in isolates of Mycobacterium tuberculosis from infants who develop culture-confirmed TB;   Intensive pharmacokinetic (PK) outcomes;   Interferon-gamma release assay (IGRA) result in women;   IGRA result in infants;   Tuberculin skin test (TST) in women;   TST for infants;   Adherence to INH/placebo for INH among women as assessed by self-report and pill count;   Occurrence of hepatotoxicity
7 Not yet recruiting Imiquimod, Fluorouracil, or Observation in Treating Patients With High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive
Conditions: Anal Intraepithelial Neoplasia;   High-grade Squamous Intraepithelial Lesion;   HIV Infection
Interventions: Drug: imiquimod;   Drug: fluorouracil;   Other: questionnaire administration;   Other: laboratory biomarker analysis
Outcome Measures: Proportion of participants achieving complete response (Arm A and B);   Proportion of participants with spontaneous regression (Arm C);   Presence of intra-anal HSIL on cytology or histology;   Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;   Proportion of participants achieving complete response or spontaneous regression;   Number of quadrants with HSIL found on biopsies;   Proportion of patients achieving complete or partial responses;   Persistence of HPV type specific infections
8 Unknown  Diagnosis of Tuberculosis Infection in HIV Co-infected Children
Conditions: Latent Tuberculosis Infection;   Tuberculosis;   HIV Infections
Outcome Measure:
9 Recruiting Searching for Persistence of Infection in Lyme Disease
Conditions: Lyme Disease;   Borrelia Burgdorferi
Interventions: Procedure: Skin Biopsy;   Device: Xenodiagnosis;   Procedure: Blood Drawing
Outcome Measures: Determine whether xenodiagnosis can detect the continued presence of B. burgdorferi in patients with Lyme disease after antibiotic therapy.;   Assess the safety of the planned xenodiagnostic procedure in humans.
10 Recruiting Evaluation of Albuminuria HIV-Infected Patients
Conditions: HIV-Associated Focal Segmental Glomerulosclerosis;   HIV-Associated Collapsing Glomerulopathy;   Proteinuria;   Albuminuria;   Renal Tubular Toxicity
Outcome Measure:
11 Recruiting Soft Tissue Ultrasound of Infections
Conditions: Soft Tissue Infections;   Cellulitis;   Abscess
Intervention: Other: Ultrasound
Outcome Measures: Discharge diagnosis;   Disposition after admission
12 Recruiting Rifampin and Efavirenz Interactions in Older Children
Conditions: HIV;   Tuberculosis
Outcome Measures: Area under time curve from time 0-24 hours(AUC0-24h) of efavirenz;   Number of children with grade 3 or 4 liver enzymes elevations compared to baseline, new onset of skin rash, nausea, vomiting or treatment modification due to drug side effects;   Number of children with efavirenz 24-hour post-dose concentration (C24h) < 1000 ng/mL;   Number of children who discontinue efavirenz therapy due to drug side effects;   Trough concentration (C24h) of efavirenz;   AUC, Cmax and clearance of efavirenz on and off rifampin-containing anti-Tb therapy in HIV/TB co-infected patients
13 Recruiting Lipopeptide Immunisation With GTU-multiHIV Trial
Condition: HIV-1 Infection
Interventions: Biological: Placebos of GTU-multiHIV B and LIPO-5 vaccines;   Biological: GTU-multHIV B vaccine and LIPO-5 vaccine
Outcome Measures: Plasma HIV-1 RNA level;   Plasma HIV-RNA after stopping antiviral treatment;   Percentage of patients with plasma HIV-RNA below 10 000 copies/mL;   Ultrasensitive proviral DNA;   CD4 T cell counts;   Percentages of patients who resumed HAART;   Percentages of patients who reached CD4 cell counts < 350/mm3 confirmed two weeks apart;   Strength of HIV-specific CD4/CD8 responses;   Proportion of responders to at least one HIV peptide pool;   Breadth of CD4/CD8+ HIV-specific responses defined as the number of HIV pools recognized among the 18 pools;   Polyfunctionality of HIV specific T cell responses evaluated by the mean proportion of CD4/CD8+ T cells producing IL-2 and/or IFN-g following ex-vivo stimulation with HIV-1 peptide pools;   Adverse Events > grade 2;   AIDS-defining events and serious non-AIDS events defined as cardiovascular diseases, kidney diseases, end stage liver diseases, non-AIDS defining malignancies except basal cellular skin cancer, and bacterial infections;   Analysis of predictive factors for plasma HIV-RNA
14 Recruiting Sofosbuvir Plus Ribavirin For Acute Hepatitis C in HIV-infected Individuals (SWIFT-C)
Conditions: HIV-1 Infection;   Hepatitis
Interventions: Drug: Ribavirin;   Drug: Sofosbuvir
Outcome Measures: SVR12 defined as HCV RNA undetectable (<LLOQ TND) of the assay at 12 weeks after date of last dose of study treatment.;   Occurrence of a Grade ≥ 2 adverse event (AE: diagnosis, sign, symptom or laboratory abnormality), Serious AE according to ICH criteria, or treatment-limiting AE (ie, an AE reported as the reason for permanent discontinuation of study treatment);   HCV RNA undetectable during study treatment;   HCV RNA undetectable after end of study treatment;   HCV virologic relapse;   Development of SOF-associated resistance mutations;   Occurrence of each type of adverse event;   Change in HIV-1 RNA from last measurement prior to start of study treatment;   Change in CD4+ cell count from last measurement prior to start of study treatment.;   Self-reported adherence to SOF;   Self-reported adherence to RBV;   Adherence as measured by SOF pill count;   Adherence as measured by RBV pill count
15 Recruiting V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds
Conditions: Lower Extremity Wound Infected;   Venous Stasis Ulcers
Interventions: Device: VAC VeraFlo with Dakins Instillation;   Device: VAC Ulta Therapy
Outcome Measure: Evaluate the change in bacteria colony-forming units using when NPWT and NPWTi on venous leg ulcers
16 Recruiting Analysis of Lyme Disease Lesions
Conditions: Erythema Migrans Lesions;   Erythema Migrans
Outcome Measure:
17 Recruiting Neurogenic Inflammation in Diabetes
Conditions: Diabetes Mellitus;   Polyneuropathies;   Arthropathy, Neurogenic
Interventions: Other: Intracutaneous injection of Candida albicans antigen.;   Procedure: Punch skin biopsy;   Other: Temperature measurement.
Outcome Measures: Induration size as a response to intracutaneous Candida albicans.;   Temperature at the injection site of the highest concentration of Candida albicans antigen on the foot, compared to the same location on the contralateral foot.;   Nature of the induration that appears as a response to intracutaneous Candida albicans evaluated by microscopy of a skin biopsy taken at the injection site of the highest concentration of Candida albicans on the foot.
18 Recruiting Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Condition: Anthrax
Outcome Measure:
19 Recruiting Screening of Children in Household Contact With Adult TB Patients in Mbarara Hospital, Uganda
Condition: Tuberculosis
Outcome Measures: Proportion of <5 year-old child contacts classified as active TB disease, LTBI or no infection;   Number of children <5 years exposed to TB in the household of adult index cases;   Number of contacts identified as active TB basing on a symptom-based approach compared with those based on chest radiography;   Proportion of contacts with HIV co-infection classified as non infected, LTBI or active TB;   Median duration of exposure to symptomatic source case among the contacts in the various classes;   Association of various risk factors with the final classification of contacts after assessment;   Proportion of children with LTBI successfully treated (prevented from developing active TB disease) among HIV-infected and uninfected children;   Proportion of children with no TB infection or disease successfully treated (prevented from developing active TB disease or LTBI);   Proportion of adverse events on treatment of TB disease, LTBI and TB exposure;   Adherence to IPT regimens
20 Recruiting Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure
Conditions: Renal Failure;   Critical Care;   Gram Positive Bacteria
Intervention: Drug: Daptomycin
Outcome Measures: area under the curve / minimum inhibitory concentration ratio of distribution and elimination of daptomycin in plasma and urine;   Cmin and Cmax of distribution and elimination of daptomycin in plasma and urine;   volume of distribution of daptomycin in plasma and urine;   clearance of distribution and elimination of daptomycin in plasma and urine;   the clinical and microbiological efficacy during Daptomycine treatment and two weeks after the end of it;   renal and muscular tolerance during Daptomycin treatment and two weeks after the end of it

These studies may lead to new treatments and are adding insight into 470 etiology and treatment.

A major focus of 470 research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss 470